Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial
Novartis (NVS) halted development of ALS drug VHB937 after it failed a Phase II trial. The company will stop the ALS program but continue studying the drug for Alzheimer's. This follows recent failures of del-desiran and pelacarsen, which erased $30B in market value. Novartis reported Q2 free cash flow of $5.6B and reaffirmed its full-year outlook, with strong sales growth in Kisqali, Kesimpta, Scemblix, Pluvicto, and Leqvio.
How this was made
The 30-second read
Why it matters
The discontinuation adds to pipeline attrition risk, potentially influencing investor sentiment and short‑term price action.
Market read
The news may trigger a modest sell‑off in Novartis and could affect sentiment toward the broader pharma sector.
What to watch
The ALS program was early‑stage; the company continues to advance other late‑stage assets like remibrutinib.
Background
Novartis has faced multiple recent trial failures, but maintains robust sales from Kisqali, Kesimpta, Scemblix, Pluvicto, and Leqvio.
Ticker impact
Novartis discontinued its mid‑stage ALS drug VHB937 after a Phase II trial failed to meet primary and secondary endpoints.
modest downside pressure in near‑term trading
Failure of a late‑stage asset can trigger sell‑off, but limited exposure and strong cash flow cushion mitigate large moves.
Market effects
Highlights risk in biotech pipelines, may cause broader caution in pharma sector.
Primarily affects US and European pharma equities.
Limited to large‑cap pharma investors worldwide.
Counterpoint
Novartis's strong cash flow and other growth products could offset the setback, presenting a buying opportunity.
Key entities
- companyNovartis AG
Global pharmaceutical company reporting the trial failure.
